Navigation Links
Behind the Landmark Weeks Case
Date:1/28/2013

BIRMINGHAM, Ala., Jan. 28, 2013 /PRNewswire/ -- In a landmark decision, the Alabama Supreme Court ruled on January 11, 2013, that a patient who alleges injury from a generic prescription drug can sue makers of the brandname drug for failing to warn about the product's risks.  The ruling, which issued in favor of Plaintiff Danny Weeks, comes after courts across the country have rejected a similar theory of liability.  In his victory, Weeks was represented by attorneys of Heninger Garrison Davis, LLC, who argued the case before the state high court.

"We now have broad daylight for our claims against the brand-makers of Reglan," commented Lew Garrison , the HGD senior partner in charge of the case.  "It is a great win for Danny and vindicates our decision to sue the brand defendants."  The suit is pending in federal court in Montgomery, Alabama, and has been stayed pending the Alabama Supreme Court's decision on the question whether a plaintiff allegedly harmed by a generic medicine can sue the brandmaker of the drug.  The federal court certified the question to the high court.

Danny Weeks alleges that he developed tardive dyskinesia, a movement disorder, from a generic version of the acid reflux drug Reglan, and that the brand-name manufacturers of the medicine (Wyeth LLC, Pfizer Inc., and Schwarz Pharma, Inc.) failed to adequately warn about its risks.  Those brand defendants asked the federal court to certify the question.

In siding with Weeks, the Supreme Court reasoned that "an omission or defect in the labeling for the brand name drug would necessarily be repeated in the generic labeling, foreseeably causing harm to a patient who ingested the generic product."  The court distinguished Weeks' claims and argument from several prior decisions in favor of brand-makers sued by patients who ingest only the generic versions of a drug.  Chris Hood , another of Weeks' attorneys at HGD, called the decision "compelling and well reasoned."

"The Alabama Supreme Court is the first and only supreme court of any state to adopt the theory of liability we advocate," Hood said.  "It correctly identified and applied basic tort principles overlooked by numerous lower courts which rejected similar theories,"  he added.  "The win is tremendously satisfying, particularly because it makes clear that Danny has recourse for his injuries."

Prior to the win, over 70 courts across the country had sided with brand‑makers in similar cases.  Courts in only two states, California and Vermont, have allowed similar claims to proceed. Furthermore, the U.S. Supreme Court decision PLIVA, Inc. v. Mensing, issued in 2011, rejected a plaintiff's suit against generic drug makers for failing to warn about their products' risks.  That decision is based on federal preemption of state tort law.  Commentators agree that it forecloses claims against generic makers for inadequate warnings on drug labels.

"Alabamians injured by generic prescriptions now can hold the brand-maker accountable for understating the risks of the drug," Chris Hood explained.  "It is the right decision, and it stands on settled law of our state."

Alabama for decades has recognized that a person harmed by someone else's misrepresentation can sue that person even if the misrepresentation was made to a third party, not to the person actually harmed by it.  Weeks' claims that the brand-makers of Reglan misinformed his prescribing doctor by understating the risk of contracting tardive dyskinesia from the drug.  The doctor is owed a duty of truth on the part of the brand-makers, Weeks' attorneys argued based on the legal rule known as the learned intermediary doctrine.

Lew Garrison , Weeks' chief attorney, believes the decision may positively influence courts in other states and thereby provide recourse for patients injured by generic replicas of brand drugs. "States which recognize the learned intermediary doctrine and liability for third‑party fraud may follow suit," he predicts.

The following language is required by Rule 7.2 of the Alabama Rules of Professional Conduct:  "No representation is made that the quality of the legal services to be performed is greater than the quality of the legal services performed by other lawyers."

Contact:

Kristi Ozley
kozley@hgdlawfirm.com
Heninger Garrison Davis
2224 1st Avenue North
Birmingham, Alabama 35203
(205) 326‑3336
Toll Free:  1‑800‑241‑9779


'/>"/>
SOURCE Heninger Garrison Davis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. International Liver Research Community United Behind World Gastroenterology Organisation Action
2. AVAC Report Finds That World is Already Falling Behind Pace to End AIDS Epidemic; Five Essential Actions Needed in 2013 to Avoid Historic Missed Opportunity
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
5. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
6. President Obama Signs Landmark Accessible Prescription Drug Label Bill
7. PRA Participates in Landmark Alzheimers Prevention Clinical Trial
8. SurgiCount Medical Achieves Landmark Product Usage And Customer Milestones
9. Fuse Science Announces Landmark Licensing Agreement with Industry Leader Macular Health
10. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
11. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016   AllCare Plus Pharmacy ... Gold Seal of Approval ® for Home ... performance standards. The Gold Seal of Approval ® ... commitment to providing safe and effective care.  ... Pharmacy underwent a rigorous on-site survey in January 2016. ...
(Date:2/9/2016)... LONDON , Feb. 9, 2016 The new report ... Acuity Business Research & Consulting group reveals that global diagnostic ultrasound ... expected to grow to US$ 7,466.3 million by 2019 at a ... market analysis of global ultrasound market has been analyzed for six ... , Asia-Pacific , Latin America ...
(Date:2/9/2016)... , Feb. 9, 2016 The global prefilled ... and it is expected to grow with a CAGR ... glass prefilled syringes segment dominated the global prefilled syringes ... --> --> The global market of ... due to increasing geriatric population, increasing demand for vaccines, ...
Breaking Medicine Technology:
(Date:2/9/2016)... , ... February 09, 2016 , ... Steven Douglas Associates ... of South Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s ... guests alike. This year the event will be held in a new, more causal ...
(Date:2/9/2016)... ... February 09, 2016 , ... Interstate ... after a disaster, announced today the acquisition of Hawaii DKI. Hawaii DKI is ... , “Investing in like-minded companies who excel at service and response helps support ...
(Date:2/9/2016)... ... February 09, 2016 , ... URise Products announces ... mobility device, the StandUp Walker. Made entirely in the USA, the StandUp Walker ... years. , StandUp Walker’s novel patent-pending design offers 2-in-1 benefits of a ...
(Date:2/9/2016)... ... 09, 2016 , ... Cirracore Enterprise Cloud, today announced that ... the cloud. Cirracore provides a secure VMware® vCloud Air based cloud that ... Transformation Solutions (TSL Partners) provides a full range of services from planning, discovery, ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), one ... ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient foundations ... , “Since our Pay It Forward program began, we are proud to have ...
Breaking Medicine News(10 mins):